Compugen (NASDAQ:CGEN) Upgraded by Truist Financial to “Strong-Buy” Rating

Truist Financial upgraded shares of Compugen (NASDAQ:CGEN) to a strong-buy rating in a report released on Wednesday morning,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of Compugen from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. HC Wainwright assumed coverage on Compugen in a research report on Wednesday, January 7th. They issued a “buy” rating and a $4.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.00.

Compugen Price Performance

Shares of CGEN opened at $2.06 on Wednesday. The company’s 50-day moving average is $1.97 and its 200-day moving average is $1.74. The firm has a market capitalization of $194.77 million, a PE ratio of 5.57 and a beta of 2.90. Compugen has a fifty-two week low of $1.13 and a fifty-two week high of $2.38.

Compugen (NASDAQ:CGEN) last announced its earnings results on Monday, March 2nd. The biotechnology company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.05 by $0.55. Compugen had a net margin of 48.57% and a return on equity of 55.68%. The business had revenue of $67.33 million during the quarter, compared to the consensus estimate of $14.30 million. Analysts predict that Compugen will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Compugen

Several hedge funds and other institutional investors have recently bought and sold shares of CGEN. Franklin Resources Inc. acquired a new stake in Compugen in the 2nd quarter worth about $56,000. Jane Street Group LLC grew its position in shares of Compugen by 1,077.0% during the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after purchasing an additional 359,785 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Compugen by 346.0% during the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 34,045 shares during the period. Two Sigma Investments LP increased its holdings in shares of Compugen by 10.6% during the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 18,929 shares during the period. Finally, Raymond James Financial Inc. raised its position in shares of Compugen by 51.0% in the third quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 34,215 shares in the last quarter. Institutional investors and hedge funds own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.